MIRM Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. (MIRM) is expected to report earnings on February 2, 2027, after the market close. The consensus earnings estimate is a loss of $0.67 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +11.3% since its last earnings release on November 3, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare liver diseases.
Sector
Healthcare
Industry
Biotechnology
Held By 1 ETFs, by dollar flow
Charts powered in part by Lightweight Charts™ by TradingView.